Acoustic Ejection Mass Spectrometry: A Fully Automatable Technology for High-Throughput Screening in Drug Discovery.


Journal

SLAS discovery : advancing life sciences R & D
ISSN: 2472-5560
Titre abrégé: SLAS Discov
Pays: United States
ID NLM: 101697563

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 27 7 2021
medline: 24 2 2022
entrez: 26 7 2021
Statut: ppublish

Résumé

Acoustic droplet ejection (ADE)-open port interface (OPI)-mass spectrometry (MS) has recently been introduced as a versatile analytical method that combines fast and contactless acoustic sampling with sensitive and accurate electrospray ionization (ESI)-MS-based analyte detection. The potential of the technology to provide label-free measurements in subsecond analytical cycle times makes it an attractive option for high-throughput screening (HTS). Here, we report the first implementation of ADE-OPI-MS in a fully automated HTS environment, based on the example of a biochemical assay aiming at the identification of small-molecule inhibitors of the cyclic guanosine monophosphate-adenosine monophosphate (GMP-AMP) synthase (cGAS). First, we describe the optimization of the method to enable sensitive and accurate determination of enzyme activity and inhibition in miniaturized 1536-well microtiter plate format. Then we show both results from a validation single-concentration screen using a test set of 5500 compounds, and the subsequent concentration-response testing of selected hits in direct comparison with a previously established matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) readout. Finally, we present the development of an in-line OPI cleaning procedure aiming to match the instrument robustness required for large-scale HTS campaigns. Overall, this work points to critical method development parameters and provides guidance for the establishment of integrated ADE-OPI-MS as HTS-compatible technology for early drug discovery.

Identifiants

pubmed: 34308708
doi: 10.1177/24725552211028135
pii: S2472-5552(22)06747-8
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

961-973

Auteurs

Roman P Simon (RP)

Drug Discovery Sciences, Boehringer Ingelheim Pharma, Biberach an der Riß, Germany.

Tim T Häbe (TT)

Drug Discovery Sciences, Boehringer Ingelheim Pharma, Biberach an der Riß, Germany.

Robert Ries (R)

Drug Discovery Sciences, Boehringer Ingelheim Pharma, Biberach an der Riß, Germany.

Martin Winter (M)

Drug Discovery Sciences, Boehringer Ingelheim Pharma, Biberach an der Riß, Germany.

Yuting Wang (Y)

Drug Discovery Sciences, Boehringer Ingelheim Pharma, Biberach an der Riß, Germany.

Amaury Fernández-Montalván (A)

Drug Discovery Sciences, Boehringer Ingelheim Pharma, Biberach an der Riß, Germany.

Daniel Bischoff (D)

Drug Discovery Sciences, Boehringer Ingelheim Pharma, Biberach an der Riß, Germany.

Frank Runge (F)

Drug Discovery Sciences, Boehringer Ingelheim Pharma, Biberach an der Riß, Germany.

Wolfgang Reindl (W)

Drug Discovery Sciences, Boehringer Ingelheim Pharma, Biberach an der Riß, Germany.

Andreas H Luippold (AH)

Drug Discovery Sciences, Boehringer Ingelheim Pharma, Biberach an der Riß, Germany.

Frank H Büttner (FH)

Drug Discovery Sciences, Boehringer Ingelheim Pharma, Biberach an der Riß, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH